JP2006509523A5 - - Google Patents

Download PDF

Info

Publication number
JP2006509523A5
JP2006509523A5 JP2004560854A JP2004560854A JP2006509523A5 JP 2006509523 A5 JP2006509523 A5 JP 2006509523A5 JP 2004560854 A JP2004560854 A JP 2004560854A JP 2004560854 A JP2004560854 A JP 2004560854A JP 2006509523 A5 JP2006509523 A5 JP 2006509523A5
Authority
JP
Japan
Prior art keywords
nucleic acid
cells
alphavirus
virus
alphavirus replicon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004560854A
Other languages
English (en)
Japanese (ja)
Other versions
JP4991108B2 (ja
JP2006509523A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/039723 external-priority patent/WO2004055166A2/en
Publication of JP2006509523A publication Critical patent/JP2006509523A/ja
Publication of JP2006509523A5 publication Critical patent/JP2006509523A5/ja
Application granted granted Critical
Publication of JP4991108B2 publication Critical patent/JP4991108B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004560854A 2002-12-13 2003-12-12 多抗原性アルファウイルス・レプリコン粒子及び方法 Expired - Lifetime JP4991108B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43305802P 2002-12-13 2002-12-13
US43329902P 2002-12-13 2002-12-13
US60/433,299 2002-12-13
US60/433,058 2002-12-13
PCT/US2003/039723 WO2004055166A2 (en) 2002-12-13 2003-12-12 Multi-antigenic alphavirus replicon particles and methods

Publications (3)

Publication Number Publication Date
JP2006509523A JP2006509523A (ja) 2006-03-23
JP2006509523A5 true JP2006509523A5 (cg-RX-API-DMAC7.html) 2007-02-08
JP4991108B2 JP4991108B2 (ja) 2012-08-01

Family

ID=32600124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004560854A Expired - Lifetime JP4991108B2 (ja) 2002-12-13 2003-12-12 多抗原性アルファウイルス・レプリコン粒子及び方法

Country Status (8)

Country Link
US (2) US20040208848A1 (cg-RX-API-DMAC7.html)
EP (1) EP1585812B1 (cg-RX-API-DMAC7.html)
JP (1) JP4991108B2 (cg-RX-API-DMAC7.html)
AU (1) AU2003297039B2 (cg-RX-API-DMAC7.html)
CA (1) CA2509973C (cg-RX-API-DMAC7.html)
DK (1) DK1585812T3 (cg-RX-API-DMAC7.html)
ES (1) ES2618309T3 (cg-RX-API-DMAC7.html)
WO (1) WO2004055166A2 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2003023026A1 (en) * 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
AU2003297039B2 (en) 2002-12-13 2009-03-05 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
US7541038B2 (en) * 2003-06-05 2009-06-02 Wyeth Holdings Corporation Fusogenic, self-propagating blebs as immunogenic compositions
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
US20090104226A1 (en) * 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
AU2005327198B2 (en) * 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
EP1856250B1 (en) * 2005-02-15 2013-07-24 The University of North Carolina At Chapel Hill New live virus vaccines
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
US20090022760A1 (en) * 2006-09-12 2009-01-22 Alphavax Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
DK2947149T3 (en) * 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
AU2010234362B2 (en) * 2009-04-08 2015-11-26 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
AU2015249175A1 (en) * 2009-04-08 2015-12-10 Alphavax, Inc. Alphavirus Replicon Particles Expressing TRP2
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
KR102266691B1 (ko) * 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
US20120107355A1 (en) 2010-10-27 2012-05-03 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
JP2014522842A (ja) * 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
BR112014008694A2 (pt) * 2011-10-11 2017-06-20 Novartis Ag moléculas de ácido nucleico policistrônico recombinante
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
AU2014204826A1 (en) * 2013-01-10 2015-07-09 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
US10174317B2 (en) 2014-02-13 2019-01-08 Synthetic Genomics, Inc. Recombinant RNA particles and methods of use
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
KR102823029B1 (ko) 2017-12-20 2025-06-20 브이엘피 테라퓨틱스 인코포레이티드 알파바이러스 레플리콘 입자
KR20210090650A (ko) 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 알파바이러스 신생항원 벡터 및 인터페론 억제제
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
TWI891771B (zh) 2020-04-17 2025-08-01 美商Ｖｌｐ醫療股份有限公司 冠狀病毒疫苗
MX2022013638A (es) 2020-04-30 2023-01-24 Vlp Therapeutics Inc Inmunoterapia con citocina.
TWI871709B (zh) 2020-06-21 2025-02-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) * 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
WO1994017813A1 (en) * 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
US20020102273A1 (en) * 1995-08-08 2002-08-01 Robert B. Grieve Use of alphavirus expression vectors to produce parasite anitgens
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5639650A (en) 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000514290A (ja) * 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
US6235290B1 (en) * 1997-07-11 2001-05-22 University Of Manitoba DNA immunization against chlaymdia infection
US5827658A (en) 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5726022A (en) * 1996-11-18 1998-03-10 Lifespan Biosciences, Inc. Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences
EP0968284B1 (en) * 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5958738A (en) 1997-03-24 1999-09-28 Roche Diagnostics Corporation Procedure for subtractive hybridization and difference analysis
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
GB9804632D0 (en) * 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
CA2327835C (en) 1998-04-08 2010-09-21 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US6844188B1 (en) * 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US6146874A (en) * 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
US6517842B1 (en) * 1998-06-29 2003-02-11 The United States Of America As Represented By The Secretary Of The Army Marburg virus vaccines
WO2000002524A2 (en) * 1998-07-10 2000-01-20 U.S. Army Medical Research Institute Of Infectious Diseases Botulinum neurotoxin vaccine
AU761021B2 (en) * 1998-07-10 2003-05-29 U.S. Medical Research Institute Of Infectious Diseases Department Of The Army Vaccine against staphylococcus intoxication
US6770479B1 (en) * 1998-07-10 2004-08-03 The United States Of America As Represented By The Secretary Of The Army Anthrax vaccine
JP2002526421A (ja) * 1998-10-05 2002-08-20 ジェンザイム・コーポレーション 癌細胞に差別的に発現する癌ワクチン設計のための遺伝子
WO2000039318A1 (en) 1998-12-31 2000-07-06 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
US6329201B1 (en) * 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
CA2373300C (en) 1999-04-14 2012-02-21 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6767699B2 (en) * 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2002020721A2 (en) 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
AU2002305914A1 (en) * 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
CA2448066A1 (en) * 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
US6936427B2 (en) * 2002-02-08 2005-08-30 Trellis Bioscience, Inc. Real time detection of intermolecular interaction
WO2004055161A2 (en) * 2002-12-12 2004-07-01 The Board Of Regents Of The University Of Texas System Large scale production of packaged alphavirus replicons
AU2003297041B2 (en) * 2002-12-13 2009-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
AU2003297039B2 (en) 2002-12-13 2009-03-05 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
US20060099587A1 (en) * 2003-06-20 2006-05-11 Johnston Robert E Alphavirus vectors having attentuated virion structural proteins
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
AU2010234362B2 (en) * 2009-04-08 2015-11-26 Alphavax, Inc. Alphavirus replicon particles expressing TRP2

Similar Documents

Publication Publication Date Title
JP2006509524A5 (cg-RX-API-DMAC7.html)
CA2567254A1 (en) Tc-83-derived alphavirus vectors, particles and methods
Ye et al. Current status of COVID‐19 (pre) clinical vaccine development
JP2010530245A5 (cg-RX-API-DMAC7.html)
Samsa et al. Self-amplifying RNA vaccines for Venezuelan equine encephalitis virus induce robust protective immunogenicity in mice
Tatsis et al. Adenoviruses as vaccine vectors
WO2003048348A3 (en) Production of viruses, viral isolates and vaccines
JP2005523318A5 (cg-RX-API-DMAC7.html)
JP2004501647A5 (cg-RX-API-DMAC7.html)
CA2509973C (en) Multi-antigenic alphavirus replicon particles and methods
HRP20221474T1 (hr) Cjepiva protiv virusa hepatitisa b
WO2002000885A3 (en) Assembly of wild-type and chimeric influenza virus-like particles (vlps)
US20210254021A1 (en) Integrated manufacturing and chromatographic system for virus production
RU2012140691A (ru) Вакцины на основе неинтегрирующегося ретровирусного вектора
WO2005035556A3 (en) Sars-coronavirus virus-like particles and methods of use
WO2008115199A3 (en) Chimeric virus vaccines
Rezaei et al. Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials
CN116218879A (zh) 一种单价广谱的正痘病毒属mRNA疫苗及其应用
JP2025169275A5 (cg-RX-API-DMAC7.html)
RU2009144980A (ru) Рецептура растворов сахаров для непрерывного ультрацентрифугирования для очистки вирусов
WO2003031583A3 (en) Generation of virus-like particles by vsv
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
CN102127554B (zh) 一种日本脑炎颗粒疫苗及其制备方法和应用
JP2009522368A5 (cg-RX-API-DMAC7.html)
CN114438079B (zh) 一种仿病毒dna多面体框架结构及其制备方法与应用